Literature DB >> 19397413

Reaching international GMP standards for vaccine production: challenges for developing countries.

Julie Milstien1, Alejandro Costa, Suresh Jadhav, Rajeev Dhere.   

Abstract

Standards for vaccine production have been increasing at a rapid rate. Current standards of good manufacturing practice (GMP) had been thought to be out of the reach of developing country vaccine producers, many of whom are in the public sector, overseen by unvalidated national regulatory authorities (NRAs). With the advent of the GMP regulations in 1963 and their application to vaccine production, even many industrialized country manufacturers with stringent NRA oversight had difficulties. This article assesses the ability of developing country manufacturers to meet GMP by the only currently available global indicator: WHO prequalification. As recently as 1996, no developing country NRA was considered able to enforce GMP compliance. That number increased to four in 2002 and six in 2006, with a concomitant increase in the number of manufacturers considered to be operating to GMP standards. Examples of the difficulties faced by manufacturers in achieving this are given, as well as implications for the future vaccine market.

Mesh:

Substances:

Year:  2009        PMID: 19397413     DOI: 10.1586/erv.09.23

Source DB:  PubMed          Journal:  Expert Rev Vaccines        ISSN: 1476-0584            Impact factor:   5.217


  4 in total

1.  Impact of BRICS' investment in vaccine development on the global vaccine market.

Authors:  Miloud Kaddar; Julie Milstien; Sarah Schmitt
Journal:  Bull World Health Organ       Date:  2014-06-01       Impact factor: 9.408

Review 2.  Adventitious agents and live viral vectored vaccines: Considerations for archiving samples of biological materials for retrospective analysis.

Authors:  Bettina Klug; James S Robertson; Richard C Condit; Stephen J Seligman; Marian P Laderoute; Rebecca Sheets; Anna-Lise Williamson; Marc Gurwith; Sonali Kochhar; Louisa Chapman; Baevin Carbery; Lisa M Mac; Robert T Chen
Journal:  Vaccine       Date:  2016-06-15       Impact factor: 3.641

Review 3.  An updated methodology to review developing-country vaccine manufacturer viability.

Authors:  Nicholas Luter; Ritu Kumar; Dai Hozumi; Tina Lorenson; Shannon Larsen; Bhavya Gowda; Amie Batson
Journal:  Vaccine       Date:  2017-06-09       Impact factor: 3.641

4.  Institutional barriers and enablers to implementing and complying with internationally accepted quality standards in the local pharmaceutical industry of Pakistan: a qualitative study.

Authors:  Fatima Tauqeer; Kirsten Myhr; Unni Gopinathan
Journal:  Health Policy Plan       Date:  2019-07-01       Impact factor: 3.344

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.